QCL

Unravel Announces Initiation of RVL001 Clinical Trial Material Manufacturing to Support Upcoming US and International Clinical Trials in Rett Syndrome

Retrieved on: 
Tuesday, March 19, 2024
Incidence, Partnership, QCL, Female, GMP, Rett syndrome, Clinical trial, Therapy, FDA, Pharmaceutical industry

BOSTON, March 19, 2024 /PRNewswire/ -- Unravel Biosciences, Inc., ("Unravel"), an AI-enabled therapeutics company established to advance drugs for complex diseases, today announced a manufacturing and development partnership with Quality Chemical Laboratories, Inc. (QCL) to manufacture RVL001 clinical trial material for use in upcoming Rett syndrome clinical trials in the US and Colombia. The collaboration with QCL is part of a broader strategy to secure the GMP manufacturing and supply chain of key proprietary technology owned by Unravel.

Key Points: 
  • Manufacturing of GMP material for clinical trials represents key step towards initiation of clinical studies.
  • The collaboration with QCL is part of a broader strategy to secure the GMP manufacturing and supply chain of key proprietary technology owned by Unravel.
  • RVL001 will be tested in the US and in Colombia in proof-of-concept clinical trials as a key path to effective Rett syndrome treatment.
  • "The initiation of manufacturing clinical trial material is a key remaining step to initiating clinical testing in our global Rett syndrome RVL001 trials."

Lobe Sciences Provides Update on L-130 Oral Psilocin Compound

Retrieved on: 
Tuesday, December 5, 2023
Mental Health, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, QCL, Psilocybin, Human, Patient, CSE, OTCQB, Partnership, Conference, Pharmaceutical industry

Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the Company’s lead clinical asset, L-130, a proprietary stabilized psilocin conjugate drug candidate, recently surpassed the 12-month stability milestone with no signs of degradation.

Key Points: 
  • Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the Company’s lead clinical asset, L-130, a proprietary stabilized psilocin conjugate drug candidate, recently surpassed the 12-month stability milestone with no signs of degradation.
  • The Company believes the updated stability report for L-130 is significant, as to date, no manufacturer of psilocin has reported a formulation of psilocin stable enough to be administered in a shelf-stable orally available formulation.
  • “L-130 was designed in collaboration with Quality Chemical Laboratories (QCL) based on the needs for a shelf stable oral molecule that can consistently deliver psilocin directly, therefore eliminating the inconsistencies and variabilities seen with psilocybin.
  • This is principally due to psilocybin’s need for first-pass metabolism” stated Philip Young, Chairman and CEO of Lobe Sciences.

Bruker Announces Majority Investment in MIRO Analytical AG, an Innovator in Compact, Highest-Precision QCL-Based Multi-Gas Analyzers (MGA)

Retrieved on: 
Wednesday, October 4, 2023
Research, Mobile, Wireless, Hardware, Oil, Gas, Environmental Health, Energy, Technology, Environment, Green Technology, Science, Climate Change, Other Science, Quantum-cascade laser, QCL, BRKR, Research institute, Compact, GHG, Multimedia, Mga (protein), Corporation, Trace gas, German Aerospace Center, TAM, Air pollution, MIRO, Coal, Bruker

Bruker Corporation (Nasdaq: BRKR) today announced a majority investment in MIRO Analytical AG , an innovative provider of fast, compact Quantum Cascade Laser (QCL)-based multi-gas analyzers for simultaneous, highest-precision monitoring of up to 10 trace gases.

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR) today announced a majority investment in MIRO Analytical AG , an innovative provider of fast, compact Quantum Cascade Laser (QCL)-based multi-gas analyzers for simultaneous, highest-precision monitoring of up to 10 trace gases.
  • MIRO’s products complement Bruker OMEGA and Matrix MG spectroscopic gas analyzers, with MIRO’s automated, compact, high-precision MGAs for real-time trace gas monitoring.
  • Dr. Morten Hundt, CEO of MIRO Analytical AG, commented: “We are delighted to become part of the Bruker family.
  • MIRO and Bruker together are a perfect fit – we share the vision as a high-quality solutions provider in trace gas analysis.

Global Quantum Cascade Laser Research Report 2023-2028 Featuring Leading Players - Thorlabs, Hamamatsu Photonics, MirSense, Emerson Electric, and Block Engineering

Retrieved on: 
Monday, September 18, 2023
Hamamatsu Photonics, Quantum-cascade laser, Medicine, CW, Market development, QCL, FP, Health, Defense, Chevrolet big-block engine, Electronics, Research, Emerson Electric, USD, Fabry–Pérot interferometer, Distributed-feedback laser, Investment, Knowledge, Growth, Region, Microscope, Telecommunications, Thorlabs, Quantum

Additionally, substantial research investments in laser technologies, coupled with government support and incentives, further propel QCL adoption.

Key Points: 
  • Additionally, substantial research investments in laser technologies, coupled with government support and incentives, further propel QCL adoption.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the Quantum Cascade Laser Market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the Quantum Cascade Laser Market across varied regions.
  • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the Quantum Cascade Laser Market.

Comera Life Sciences Announces Collaboration with Quality Chemical Laboratories to Secure Proprietary Supply of SQore Excipients

Retrieved on: 
Thursday, July 20, 2023
GMP, Partnership, QCL, CMRA, Science, Excipient, Safety, Pharmaceutical industry

WOBURN, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Comera” or the “Company”), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced a partnership with Quality Chemical Laboratories, Inc. (QCL) to manufacture one of Comera’s lead SQore™ excipients, as part of a broader strategy to secure the GMP manufacturing and supply chain of key proprietary technology owned by the Company.

Key Points: 
  • WOBURN, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. ( Nasdaq: CMRA ) (“Comera” or the “Company”), a life sciences company developing a new generation of biologic medicines to improve patient access, safety, and convenience, today announced a partnership with Quality Chemical Laboratories, Inc. (QCL) to manufacture one of Comera’s lead SQore™ excipients, as part of a broader strategy to secure the GMP manufacturing and supply chain of key proprietary technology owned by the Company.
  • “In addition to the substantial investment we have made in the science behind our proprietary SQore platform, we are building value by expanding our SQore patent portfolio and ensuring supply and access to our lead SQore excipients,” said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera.
  • “There has been a growing trend towards bringing back manufacturing of critical, high-value technologies such as pharmaceuticals to the United States to reduce supply risk, ensure high quality production and improve regulatory compliance.
  • Comera’s proprietary SQore platform integrates computational modeling, a robust library of excipients, and advanced formulation engineering to expedite the development of patient-preferred biotherapeutic formulations, while fostering novel intellectual property creation.

Military Mid IR Sensors Market Report 2023: Military Mid IR Market is Forecast to Reach $130 Billion by 2029 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 3, 2023
Semiconductor, Health, Defense, Technology, Health Technology, Military, Medicine, IR, QCL, MID, Smartphone, Internet, Toluene, Growth, Research, Benzene, Disease, Medical imaging

The "Military Mid IR Sensors Market Research Forecasts 2023-2029" report from Wintergreen Research, Inc has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Military Mid IR Sensors Market Research Forecasts 2023-2029" report from Wintergreen Research, Inc has been added to ResearchAndMarkets.com's offering.
  • Military mid IR markets at $34.19 billion in 2022 are anticipated to reach $130 billion by 2029 as price performance increases and unit costs decrease from $3,000 per unit to $900 per high-end unit.
  • Military medical applications include human breath monitoring, glucose sensing, cancer detection and diagnostics, eye surgery, and environmental health monitoring.
  • Worldwide military mid IR sensor markets are poised to continue to achieve significant growth with the implementation of smartphone apps.

Military Mid IR Sensors Market Shares and Forecasts Report 2023-2029

Retrieved on: 
Monday, June 26, 2023
IR, QCL, Health, MID, Smartphone, Internet of things, Microscopy, Intelligence, Internet, Traction, Growth, Research, Ceramic, Instrumentation, Medical imaging

DUBLIN, June 26, 2023 /PRNewswire/ -- The "Military Mid IR Sensors Market Shares and Forecasts, 2023-2029" report from Wintergreen Research, Inc has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 26, 2023 /PRNewswire/ -- The "Military Mid IR Sensors Market Shares and Forecasts, 2023-2029" report from Wintergreen Research, Inc has been added to ResearchAndMarkets.com's offering.
  • Mid IR is extending use beyond military applications to commercial systems, including the Internet of Things where sensors become part of network systems.
  • Mid IR sensors are the base of the military light, image, and gas sensor control systems.
  • Mid IR has extended use to all military applications, and mid ir sensors have become part of network systems.

Media Release: Take your spectroscopy to the next level

Retrieved on: 
Saturday, March 11, 2023
IRsweep, ARD International Music Competition, QCL, Research

With their new IRis-C, they are making spectroscopy more accessible for a variety of lab and field applications.

Key Points: 
  • With their new IRis-C, they are making spectroscopy more accessible for a variety of lab and field applications.
  • The new spectrometer is based on dual-comb spectroscopy – a Nobel-prize winning method that provides high-resolution and high-speed analysis of the molecular composition of samples.
  • The light sources are quantum cascade laser frequency combs, which are known for their stability and high optical power.
  • The spectrometer's compact size and cost-effectiveness make it ideal for a variety of settings, including academic and industrial research.

New CDMO Client, Quality Chemical Laboratories, Benefits From InstantGMP's All-in-One Quality & Manufacturing System and Software Auditing for GMP Manufacturers

Retrieved on: 
Tuesday, November 1, 2022
Efficiency, Software, GLOBE, SOP, Documentation, Time, Industry, Compliance, QCL, CDMO, FDA, GMP, Medical device

Quality Chemical Laboratories was founded in 1998 as a raw material testing laboratory and has continuously expanded capabilities and service offerings.

Key Points: 
  • Quality Chemical Laboratories was founded in 1998 as a raw material testing laboratory and has continuously expanded capabilities and service offerings.
  • For over 25 years, this leading CDMO has provided GMP-compliant formulation development and manufacturing services for the pharmaceutical industry.
  • To ensure that the InstantGMP PRO system was validated, Quality Chemical Laboratories conducted an extensive software vendor audit .
  • To learn more about InstantGMP PRO 's new features and software auditing processes for GMP manufacturers, contact us to schedule a demo nstration.

New CDMO client, Quality Chemical Laboratories, benefits from InstantGMP's all-in-one quality & manufacturing system and software auditing for GMP manufacturers

Retrieved on: 
Tuesday, October 11, 2022
Software, Time, SOP, QCL, Good manufacturing practice, Company, Industry, Documentation, Good, CDMO, Efficiency, FDA, Synthase, Compliance, GMP, Fine chemical, Medical device

CARY, N.C., Oct. 11, 2022 /PRNewswire-PRWeb/ -- InstantGMP, the originators of the all-in-one manufacturing and quality system, is proud to welcome a new contract development and manufacturing organization, Quality Chemical Laboratories (QCL), to their growing client base.

Key Points: 
  • Quality Chemical Laboratories was founded in 1998 as a raw material testing laboratory and has continuously expanded capabilities and service offerings.
  • For over 25 years, this leading CDMO has provided GMP compliant formulation development and manufacturing services for the pharmaceutical industry.
  • To ensure that the InstantGMP PRO system was validated, Quality Chemical Laboratories conducted an extensive software vendor audit .
  • As a manufacturing software company, InstantGMP pioneered accessible, easy-to-use electronic batch record software for products manufactured using GMPs.